Hematological parameters in sickle cell anemia patients with and without priapism

Sagir G. Ahmed,* Umma A. Ibrahim,† Abba W. Hassan ‡

BACKGROUND: Priapism was associated with certain hematological parameters in sickle cell anemia (SCA) patients in one report but not in another. We studied differences in haematological parameters between SCA patients with and without priapism.

PATIENTS AND METHODS: Eighteen patients with SCA who presented with acute priapism during the years 2001-2004 were compared with age- and sex-matched SCA patients without priapism with respect to hematocrit, reticulocyte count, level of irreversibly sickled cells (ISC), percentage of haemoglobin F (Hb F), total leucocyte and platelet counts.

RESULTS: SCA patients with priapism had a mean hematocrit of 0.28 L/L, which was significantly higher than the mean hematocrit value of 0.24 L/L (P<0.05) in patients without priapism. The mean reticulocyte count of 8% in patients with priapism was significantly lower than mean reticulocyte count of 12% (P<0.05) in patients without priapism. The level of ISC of 3% in patients with priapism was significantly lower than the level of 6.5% (P<0.05) in patients without priapism. There was no statistically significant difference in the mean levels of Hb F (7% vs. 8%). Patients with priapism had a mean leucocyte count and mean platelet count that did not significantly differ from values in patients without priapism.

CONCLUSIONS: SCA patients with priapism had a lower rate of hemolysis, resulting in a higher hematocrit and greater blood viscosity, which increased the risk of corpora cavernosal sickling and blockade. Hence, a relatively high hematocrit is a risk factor for the development of priapism in patients with sickle cell anemia.
thelial damage and subsequent exposure of sub-endothelial structures and collagen, resulting in platelet activation and aggregation within the microvasculature.\textsuperscript{6,7} Furthermore, recent studies suggest that sickled erythrocytes increase vascular endothelial production of adhesion molecules, which creates a situation that favors intravascular cellular adhesions, stasis and prolongation of blood flow transit time, thereby increasing the chances of sickling of erythrocytes.\textsuperscript{8} These events finally lead to a blockade of small blood vessels, resulting in tissue infarctions, which present clinically as the characteristic painful vaso-occlusive crises that commonly affects the bones. The effect of vascular occlusion in SCD is by no means restricted to the bones. Many other organs of the body, including the central nervous system, the lungs, the penis and the kidneys are particularly afflicted and multiple organ damage may also result.\textsuperscript{9} In addition, sickling drastically shortens the life span of red cells leading to a chronic haemolytic anemia and jaundice with the possibility of formation of bilirubin gall stones in the long run.\textsuperscript{8}

Priapism is a genital manifestation of SCD presenting as an unwanted painful erection that occurs in male patients with sickle cell anemia. It is caused by sickling episodes and thrombosis within the channels of the corpora cavernosa, leading to stasis and protracted congestion of the penile erectile tissues.\textsuperscript{9,10} The clinical presentation can be acute, recurrent or stuttering.\textsuperscript{8} The engorgement in priapism typically affects the corpora cavernosa and usually spares the glans penis and corpus spongiosum, except in a minority of cases in which the corpus spongiosum is also engorged.\textsuperscript{9} Priapism is injurious to the erectile tissues, and if severe erection persists for more than a day, partial or complete impotence may occur as a result of corpora cavernosal fibrosis.\textsuperscript{10} Hence, patients with priapism require careful assessment and prompt and effective management. A number of changes in haematological parameters had earlier been reported as being important predisposing factors for the development of priapism in patients with SCD. Among Jamaican patients with sickle cell anemia, priapism was found to be significantly associated with low hemoglobin F (Hb F) levels and high platelet counts.\textsuperscript{11} However, a report from the United State indicated that there were no significant differences between hematological parameters of SCD patients with and without priapism.\textsuperscript{9} We studied the hematological parameters of Nigerian patients with sickle cell anemia (SCA) presenting with priapism in comparison to SCA patients without any history of priapism. The data was analyzed to determine any significant hematological features that might be associated with the development of priapism in Nigerian patients with SCA as seen in Maiduguri, in northeast Nigeria.

Patients and Methods

Hematological parameters, including hematocrit, reticulocyte count, level of irreversibly sickled cells (ISC), percentage of Hb F, and total leukocyte and platelet counts were measured in 18 patients (aged 16-42 years) with SCA (Hb SS) who presented with acute priapism at the University of Maiduguri Teaching Hospital (UMTH), northeast Nigeria, during the years 2001 to 2004. The patients presented with acute priapism with no bone pain or other features of generalized vaso-occlusive crises. Blood samples for analyses were taken at the time of presentation and before initiating any form of treatment. The mean values of these parameters were then compared with those of an equal number of age- and sex-matched sickle cell anemia patients in steady state and with no history of priapism. All the patients included in this study were registered with the hematology clinic of the UMTH, and in each case the diagnosis of SCA was established by a positive sickling test and hemoglobin electrophoresis at a pH of 8.6 on cellulose acetate paper.

The hematocrit, total leukocyte and platelet counts were determined by automation using Beckman Coulter AcT-8, and white cell count errors due to the presence of nucleated red cells were appropriately corrected using manual differential counts in all cases.\textsuperscript{12} The reticulocyte counts were determined manually from blood films made after samples were incubated with brilliant cresyl blue; the reticulocytes were identified and counted as percentages of the total red cells enumerated under high power microscope fields as described by Dacie and Lewis.\textsuperscript{12} The levels of irreversibly sickled cells (ISC) were manually estimated as percentages of the total red cells enumerated from blood films made with the Leishman stain and examined under high power microscope fields as described by Dacie and Lewis.\textsuperscript{13} Percentages of Hb F were also determined manually by the modified Betke method as described by Dacie and Lewis.\textsuperscript{13} All procedures and tests conducted on the patients in this study were conducted in accordance with local ethical codes and were carried out after informed consent was obtained in each case.

Patients with and without priapism were compared with respect to the mean values and standard deviations of the determined parameters. In this report, the mean values and standard deviations were determined manually and the statistical significance of any differences in mean values were assessed using the Student t test and a probability level of $P<0.05$ was taken as significant.
Results
The mean values and standard deviations of hematological parameters found among SCA patients with priapism and those without a history of priapism are shown in Table 1. Patients with priapism had a mean hematocrit of 0.28 L/L, which was significantly higher than the mean hematocrit value of 0.24 L/L ($P<0.05$) in patients without priapism. The mean reticulocyte count of 8% in patients with priapism was significantly lower than mean reticulocyte count of 12% ($P<0.05$) in patients without priapism. The level of ISC of 3% in patients with priapism was significantly lower than the 6.5% ($P<0.05$) in patients without priapism. However, there was no statistically significant difference in the mean levels of Hb F of 7% and 6% in patients with and without priapism, respectively. Patients with priapism had a mean leukocyte count of $11.8 \times 10^9$/$L$ and a mean platelet count of $450 \times 10^9$/$L$, which did not significantly differ from the mean leukocyte count of $12.3 \times 10^9$/$L$ and mean platelet count of $460 \times 10^9$/$L$ in patients without priapism. However, the absence of a significant difference in platelet count between our patients with and without priapism is at variance with earlier reports, which suggested that SCA patients with priapism had a significantly higher platelet count as compared with SCA patients who had no history of priapism. The finding of elevated mean levels of both platelet and leukocyte counts in our patients is consistent with previous studies, which showed that both thrombocytosis and leucocytosis were common in Nigerian patients with SCA.

Our SCA patients with priapism had a significantly higher mean value for the hematocrit and a lower mean reticulocyte count and ISC as compared with their counterparts who had no history of priapism. This data would suggest that the patients with priapism had a lower rate of steady-state hemolysis in comparison with their counterparts who had no history of priapism. This is supported by an earlier study, which found that the reticulocyte count and ISC are directly related to the rate of hemolysis and are important determinants of hemolysis in sickle cell anemia. The higher mean hematocrit among SCA patients with priapism in this study is interpreted to correlate well with their lower mean reticulocyte count and lower mean ISC, both of which are indicative of lower rates of steady-state sickling and hemolysis. These findings would suggest that SCA patients with priapism had clinically milder disease in terms of hemolysis as compared with their counterparts who had no history of priapism. This is supported by earlier studies, which showed that the rate of steady-state hemolysis and levels of ISC were significant markers of disease severity in SCA. Variations in levels of Hb F accounts for much of the clinical heterogeneity observed in patients with SCA, and the Hb F level has emerged as an important prognostic factor as higher levels are generally associated with lower rates of sickling and hemolysis. However, the observed differences in terms of rates of sickling and hemolysis

### Table 1. Haematological parameters in sickle cell anemia patients with and without priapism.

| Parameters (mean±SD) | Patients with priapism (n=18) | Patients without priapism (n=18) | Statistical significance |
|----------------------|-------------------------------|---------------------------------|-------------------------|
| Hematocrit (L/L)     | 0.28±0.02                     | 0.24±0.03                      | $P<0.05$                |
| Reticulocyte count (%)| 8±1.5                         | 12±2                           | $P<0.05$                |
| Level of irreversibly sickled cells (%)| 3±0.5                     | 6.5±1                          | $P<0.05$                |
| Hb F level (%)       | 7±1                           | 6±1.2                          | $P<0.05$                |
| Total leucocyte count ($\times 10^9$/L) | 11.8±3                     | 12.3±2.5                       | $P<0.05$                |
| Platelet count ($\times 10^9$/L)    | 450±50                        | 460±52                         | $P<0.05$                |

Values are mean ± standard deviation.
between our patients with and without priapism could not be explained on the basis of Hb F levels since both categories of patients had only mildly elevated levels (7% and 6%, respectively) which were not different statistically. This finding is at variance with previous reports suggesting that SCA patients with priapism had significantly lower Hb F levels as compared with patients who had no history of priapism. However, our finding of mildly elevated levels of Hb F in both patient groups is consistent with previous studies that reported Hb F levels of less than 10% among Nigerian and other African patients with SCA, which is at variance with the considerably higher levels generally seen in Middle Eastern patients. Therefore, certain unidentified factors other than Hb F levels may be responsible for the observed differences in the rates of sickling and hemolysis between the two categories of SCA patients in this study since many genetically determined factors influence the variability in clinical expression of SCA.

Our findings suggest an association between the hematocrit and priapism. This is interpreted to be a reflection of the fact that whole blood hyperviscosity is a major contributory factor in the pathogenesis of vascular occlusion in SCA. Studies have shown that the viscosity of oxygenated sickle blood was 1.5-fold that of normal blood at equal shear rates and was increased to 10-fold that of normal blood upon deoxygenation. Furthermore, a higher hematocrit in patients with SCA was found to be associated with a greater increase in whole blood viscosity, which causes a diminished blood flow and increases the tendency towards sickling, thrombus formation and vascular occlusion.

Therefore, our findings in this study suggest that the relatively higher hematocrit seen in SCA patients with priapism could be an important causative factor since a higher hematocrit would lead to higher blood viscosity, which increases the risk of sickling, thrombosis and vascular occlusion within the channels of the corpora cavernosa, leading to the development of priapism. In fact, earlier studies had shown that a higher hematocrit was also associated with greater risks of developing other serious complications of SCA in which vascular occlusion is an important factor, such as stroke, acute chest syndrome, acute multi-organ dysfunction syndrome, avascular necrosis of the femoral head and retinopathy, all of which were thought to be related to higher blood viscosity. Although the result of this study did not find any significant differences in leukocyte and platelet counts between SCA patients with priapism and those without priapism, it should however be appreciated that blood viscosity is also affected by the number of circulating leukocytes and platelets, which can act jointly and subtly with the hematocrit to raise blood viscosity and increase the risk of vascular occlusion and priapism in SCA. Hence, it may not be possible to precisely quantify the extent of the risk of priapism that can occur due to a higher hematocrit in patients with SCA because of the variable rheological effects of leukocytes and platelets. Nonetheless, it may be anticipated that the risk of priapism in SCA patients with a higher hematocrit would be greater if such patients also have leukocytosis and/or thrombocytosis. We conclude that a relatively high hematocrit is a risk factor for the development of priapism in patients with sickle cell anemia.
References

1. Davies SC, Drioli L. Management of sickle cell disease. Br Med J, 1997; 315: 656-660.
2. Khalil MI, Padunoo MKO, Omotara BA, Ezimah ACU. Evaluation of population genetics of HbS in rural population of Borno State, North-East Nigeria. Medcare J, 1992; 5(1): 15-20.
3. Akinugbe OD. Sickle Cell Disease. In: Non-Communicable Diseases in Nigeria. Akinugbe OD, ed. 1st ed, Federal Ministry of Health, Lagos, 1992; 45-52.
4. Akinugbe OD. Protection against lethal malaria in transgenic mice expressing sickle cell haemoglobin. Blood, 1996; 87:1600-1603.
5. Akinwaju OD. A profile of sickle cell anaemia in Nigeria. Ann N Y Acad Sci 1989; 546: 126-136.
6. Kaul DK, Fabry ME, Nagel RI. The pathophysiology of vascular obstruction in the sickle cell syndromes. Blood Rev, 1996; 10:29-44.
7. Mehta P, Mehta J. Circulating platelet aggregates in sickle cell disease. Stroke, 1979; 10:464-468.
8. Shia TY, Uddin MM, McIntire LV. Perfusion with sickle cell erythrocytes up-regulates ICAM-1 and VCAM-1 genes expression in cultured human endothelial cells. Blood, 2000; 95:3233-3242.
9. Fowler JE, Koshy M, Chinn SK. Priapism associated with the sickle cell hemoglobinopathy: prevalence, natural history and sequelae. J Urol, 1991; 145:65-68.
10. Kluft C, Yeboah ED. Bladder, Urethra and Penis. In: Principles and Practice of Surgery, including Pathology in the Tropics. Badoe EA, Archampong ED, Jaja MOA, eds. 2nd ed, Ghana Publishing Corporation, Tema, 1994; 778-818.
11. Edmond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med, 1980; 140: 1434-1437.
12. Dacie JV, Lewis SM. Basic Haematological Techniques. In: Practical Haematology. Dacie JV, Lewis SM, eds. 7th Ed, Churchill Livingstone, London, 1991; 37-66.
13. Dacie JV, Lewis SM. Preparation and Staining Methods for Blood and Marrow. In: Practical Haematology. Dacie JV, Lewis SM, eds. 7th Ed, Churchill Livingstone, London, 1991; 75-85.
14. Dacie JV, Lewis SM, White JM, Marah GW. Investigation of Abnormal Haemoglobins and Thalassaemia. In: Practical Haematology. Dacie JV, Lewis SM, eds. 7th Ed, Churchill Livingstone, London, 1991; 227-257.
15. Boggs DR, Hyde F, Srodes C. An unusual pattern of neutrophil kinetics in sickle cell anemia. Blood; 1973, 41:59-62.
16. Buchanan GR, Gladder BE. Leucocyte counts in children with sickle cell disease. Comparative values in steady state, vaso-occlusive crisis and bacterial infections. Am J Dis Child, 1970; 132: 396-398.
17. Freedman ML, Karpatick S. Elevated platelet count and megathrombocytes number in sickle cell anemia. Blood; 1975; 45: 579-582.
18. Schwartz AD. The splenic platelet reservoir in sickle cell anemia. Blood; 1972; 42: 678-683.
19. Onwukeme KE. Haematological indices of Nigerians with sickle cell anemia. Nig Med Pract, 1978; 132: 396-398.
20. Powers D, Chan LS, Schroeder WA. The variable expression of sickle cell disease is genetically determined. Sem Hematol, 1990; 27: 360-376.
21. Schmalzer EA, Lee JD, Brown AK. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels: Implications for transfusion. Transfusion, 1987; 27:226-233.
22. Chien S, Usami S, Bertles JF. Abnormal rheology of oxygenated blood in sickle cell anemia. J Clin Invest, 1970; 49: 623-634.
23. Rosse WF. Blood Viscosity in Sickle Cell Disease. American Society of Hematology Education Program, 2000; 1: 3-6.
24. Castro O, Brambilla DJ, Thorington BD. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood, 1994; 84: 643-649.
25. Hassell KL, Eckman JR, Lane PA. Acute Multiorgan Failure Syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med, 1994; 96: 155-162.
26. Milner PF, Kraus AP, Sebes JI. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med, 1991; 325: 1476-81.
27. Serjeant GR, Serjeant BE, Milan PF. The irreversibly sickled cell: A determinant of haemolysis in sickle cell anaemia. Br J Haematol, 1969; 17: 527-529.
28. Serjeant GR, May H, Stuart J, Serjeant BE. An unusual pattern of neutrophil kinetics in sickle cell anemia. Blood; 1973, 41:59-62.
29. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E. Pain in sickle cell disease. N Engl J Med, 1991; 325: 11-6.
30. Marcus SJ, Kinney TR, Schultz WH. Quantitative analysis of erythrocytes containing foetal hemoglobin in children with SCD. Am J Hematol, 1997; 54: 40-45.
31. Platt OS, Thorington BD, Milner PF, Rosse WF. Vichinsky E. Pain in sickle cell disease. N Engl J Med, 1991; 325: 11-6.